Cipla Shares Dip 2.99% Despite Strong Q4 Earnings

shares traded weak on May 14, 2025, despite reporting profit growth in Q4FY25, as investor sentiment remained cautious over margin outlook. The stock opened negatively and declined by as much as 2.99% from the previous close. The company clarified that the US government’s drug pricing executive order, aimed at reducing prescription costs, is not expected to impact Indian generic players. However, concerns around pricing pressure and future margins weighed on the stock, overshadowing the earnings beat. Disclaimer: This post is for informational purposes only and does not constitute trading or investment advice.